Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cushing's disease

ENEA 2010

22 - 25 Sep 2010

Published: 23 Nov 2010

Views: 6627

Rating:

Save

Prof Annamaria Colao - Federico II University of Naples, Italy

Prof Annamaria Colao speaks to ecancertv about Cushing’s disease; the causes of the disease, who is most susceptible and the difficulties of diagnosis. Cushing’s disease is very severe and associated with a 50% mortality within five years. The only approved treatment is surgery followed by radiotherapy but this treatment is only effective in 50% of patients. Prof Colao discusses drugs that are being investigated as possible treatments for Cushing’s disease and the need to raise awareness of this problem.

Categories:
Hormones/endocrine

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

More from ecancer